Discovery of PF-06855800, a SAM competitive PRMT5 inhibitor with potent antitumor activity

被引：4

作者：

Mcalpine, Indrawan J. ^{[1
]}

Tatlock, John ^{[1
]}

Billitti, Joseph ^{[1
]}

Braganza, John ^{[1
]}

Brooun, Alexei ^{[1
]}

Deng Ya-Li ^{[1
]}

Hirakawa, Brad ^{[1
]}

Jensen-Pergakes, Kristen ^{[1
]}

Kumpf, Robert ^{[1
]}

Liu, Wei ^{[1
]}

Maegley, Karen ^{[1
]}

McTigue, Michele ^{[1
]}

Patman, Ryan ^{[1
]}

Rui, Eugene ^{[1
]}

Scales, Stephanie ^{[1
]}

Spiegel, Noah ^{[1
]}

Tran-Dube, Michelle ^{[1
]}

Wang, Fen ^{[1
]}

Wang, Zhenxiong ^{[1
]}

Yamazaki, Shinji ^{[1
]}

Zhang, Tao ^{[1
]}

Wythes, Martin ^{[1
]}

机构：

[1] Pfizer Global R&D, San Diego, CA USA

来源：

CANCER RESEARCH | 2018年 / 78卷 / 13期

关键词：

D O I：

10.1158/1538-7445.AM2018-4857

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

4857

引用

页数：2

共 50 条

[21] Discovery of Covalently-bound, First-in-Class Allosteric Inhibitor of PRMT5
McKinney, D.
Ranaghan, M.
McMillan, B.
Brousseau, M.
O'Keefe, M.
Moroco, J.
Singh, R.
Besnik, B.
McCarren, P.
Mulvaney, K.
Sellers, W.
Ianari, A.
EUROPEAN JOURNAL OF CANCER, 2020, 138 : S1 - S1
[22] Discovery of TNG462: A Highly Potent and Selective MTA-Cooperative PRMT5 Inhibitor to Target Cancers with MTAP Deletion
Cottrell, Kevin M.
Briggs, Kimberly J.
Tsai, Alice
Tonini, Matthew R.
Whittington, Douglas A.
Gong, Shanzhong
Liang, Colin
Mccarren, Patrick
Zhang, Minjie
Zhang, Wenhai
Huang, Alan
Maxwell, John P.
JOURNAL OF MEDICINAL CHEMISTRY, 2025, 68 (05) : 5097 - 5119
[23] Identification of a First-in-Class PRMT5 Inhibitor with Potent in Vitro and in Vivo Activity in Preclinical Models of Mantle Cell Lymphoma
Penebre, Elayne
Kuplast, Kristy G.
Majer, Christina R.
Johnston, L. Danielle
Rioux, Nathalie
Munchhof, Michael
Jin, Lei
Boriak-Sjodin, P. Ann
Wigle, Tim J.
Jacques, Suzanne L.
West, Kip A.
Lingaraj, Trupti
Stickland, Kimberly
Ribich, Scott A.
Raimondi, Alejandra
Porter-Scott, Margaret
Waters, Nigel J.
Pollock, Roy M.
Smith, Jesse J.
Barbash, Olena
Kruger, Ryan G.
Copeland, Robert A.
Moyer, Mikel P.
Chesworth, Richard
Duncan, Kenneth W.
BLOOD, 2014, 124 (21)
[24] PF-06939999, a potent and selective PRMT5 inhibitor, in patients with advanced or metastatic solid tumors: A phase 1 dose escalation study.
Ahnert, Jordi Rodon
Perez, Cesar Augusto
Wong, Kit Man
Maitland, Michael L.
Tsai, Frank
Berlin, Jordan
Liao, Kai Hsin
Wang, I-Ming
Markovtsova, Lada
Jacobs, Ira A.
Cavazos, Nora
Li, Meng
Tolcher, Anthony W.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[25] AZ-PRMT5i-1: A potent MTAP-selective PRMT5 inhibitor with pharmacodynamic and monotherapy anti-tumor activity in MTAP-deleted tumours
Lynch, James T.
Moore, Shaun
Barrantes, Ivan Del Barco
Bradshaw, Lauren
Chambers, Chris
Hong, Ted
Cooke, Sophie
Urosevic, Jelena
Vazquez-Chantada, Mercedes
Smith, James M.
Cronin, Anna
Recolin, Benedicte
Gill, Sonja
Critchlow, Susan
Chan, Ho Man
Dean, Emma
CANCER RESEARCH, 2023, 83 (07)
[26] Discovery of a Potent Inhibitor of Anaplastic Lymphoma Kinase with in Vivo Antitumor Activity
Ott, Gregory R.
Tripathy, Rabindranath
Cheng, Mangeng
McHugh, Robert
Anzalone, Andrew V.
Underiner, Ted L.
Curry, Matthew A.
Quail, Matthew R.
Lu, Lihui
Wan, Weihua
Angeles, Thelma S.
Albom, Mark S.
Aimone, Lisa D.
Ator, Mark A.
Ruggeri, Bruce A.
Dorsey, Bruce D.
ACS MEDICINAL CHEMISTRY LETTERS, 2010, 1 (09): : 493 - 498
[27] Discovery of new potent protein arginine methyltransferase 5 (PRMT5) inhibitors by assembly of key pharmacophores from known inhibitors
Zhu, Kongkai
Song, Jia-Li
Tao, Hong-Rui
Cheng, Zhi-Qiang
Jiang, Cheng-Shi
Zhang, Hua
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2018, 28 (23-24) : 3693 - 3699
[28] Discovery of novel potent and selective inhibitors of PRMT5 with anti-tumor activity in hepatocellular carcinoma and lung pre-clinical models
Gonzalvez, Francois
Vandyck, Koen
Debing, Yannick
Gupta, Kusum
Misner, Dinah
Zhang, Qingling
Liu, Jyanwei
Stoycheva, Antitsa
Stevens, Sarah
Symons, Julian
Beigelman, Leonid
Raboisson, Pierre
Deval, Jerome
CANCER RESEARCH, 2020, 80 (16)
[29] Discovery of AMG 193, an MTA-Cooperative PRMT5 Inhibitor for the Treatment of MTAP-Deleted Cancers
Pettus, Liping H.
Bourbeau, Matthew
Tamayo, Nuria A.
Amegadzie, Albert
Beylkin, Diane
Booker, Shon K.
Butler, John
Frohn, Michael J.
Kaller, Matthew R.
Kohn, Todd
Lanman, Brian A.
Li, Kexue
Liu, Qingyian
Ma, Vu
Medina, Jose
Minatti, Ana E.
Lopez, Patricia
Manoni, Francesco
Pickrell, Alex
Weires, Nicholas
Andersson, Jan
Cowland, Sanne
Glad, Sanne
Sarvary, Ian
Vestergaard, Mikkel
Li, Weikun
Ghimire-Rijal, Sudipa
Mardirossian, Narbe
Mukund, Susmith
Chen, Qing
Lo, Mei-Chu
Ngo, Rachel
Khetan, Jawahar
Madoux, Franck
Sanders, Christiana
Sharma, Pooja
Wang, Paul
Bruenner, Bernd
Mccloud, Stuart
Ponce, Manuel
Soto, Marcus
Wahlstrom, Jan
Xie, Fang
Yang, Yajing
Liu, Siyuan
Tan, Hong
Policheni, Antonia
Caenepeel, Sean
Slemmons, Katherine K.
Belmontes, Brian
JOURNAL OF MEDICINAL CHEMISTRY, 2025,
[30] AMG 193, a Clinical Stage MTA-Cooperative PRMT5 Inhibitor, Drives Antitumor Activity Preclinically and in Patients with MTAP-Deleted Cancers
Belmontes, Brian
Slemmons, Katherine K.
Su, Chun
Liu, Siyuan
Policheni, Antonia N.
Moriguchi, Jodi
Tan, Hong
Xie, Fang
Aiello, Daniel Andrew
Yang, Yajing
Lazaro, Raul
Aeffner, Famke
Rees, Matthew G.
Ronan, Melissa M.
Roth, Jennifer A.
Vestergaard, Mikkel
Cowland, Sanne
Andersson, Jan
Sarvary, Ian
Chen, Qing
Sharma, Pooja
Lopez, Patricia
Tamayo, Nuria
Pettus, Liping H.
Ghimire-Rijal, Sudipa
Mukund, Susmith
Allen, Jennifer R.
Devoss, Jason
Coxon, Angela
Rodon, Jordi
Ghiringhelli, Francois
Penel, Nicolas
Prenen, Hans
Glad, Sanne
Chuang, Chen-Hua
Keyvanjah, Kiana
Townsley, Danielle M.
Butler, John R.
Bourbeau, Matthew P.
Caenepeel, Sean
Hughes, Paul E.
CANCER DISCOVERY, 2025, 15 (01) : 139 - 161

← 1 2 3 4 5 →